Zoe Kathleen Mcquilten - Epidemiology

Author Information

Zoe Kathleen McQuilten is a distinguished researcher affiliated with the Australian and New Zealand Intensive Care Research Centre at Monash University in Melbourne, Australia. She is also associated with the Transfusion Research Unit within the Department of Epidemiology and Preventive Medicine at Monash University and serves in the Department of Haematology at Monash Health in Melbourne. Her academic and clinical roles underscore her extensive involvement in medical research and healthcare.

Research Contributions

Dr. Zoe Kathleen McQuilten has made significant contributions to the field of epidemiology and haematology, with a particular focus on major haemorrhage management, antiplatelet therapy in COVID-19, and bleeding complications on extracorporeal life support. Her research also extends to the study of multiple myeloma among Māori and Pacific peoples in New Zealand, and the economic evaluations of patient blood management guidelines in cardiac surgery. Additionally, she has investigated the determinants of passive antibody effectiveness in SARS-CoV-2 infection and the quality of life improvements in patients undergoing azacitidine-based therapy for myelodysplasia.

Aliases

Zoe Kathleen McQuilten is also known by several aliases in her publications, including Zoe K. Mcquilten, Z Mcquilten, Zoe K Mcquilten, Z K Mcquilten, and Z. K. Mcquilten.

Publication and Citation Metrics

Metric	Value
Total Citations	4738
H-index	34
Total Papers	218

Publications:

International Forum on the Management of Major Haemorrhage: Responses.

DOI: 10.1111/vox.13243

Year: 2022

Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.

DOI: 10.1001/jama.2022.2910

Year: 2022

Māori and Pacific peoples with multiple myeloma in New Zealand are younger and have inferior survival compared to other ethnicities: a study from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

DOI: 10.1016/j.clml.2022.04.004

Year: 2022

International Forum on the Management of Major Haemorrhage: Summary.

DOI: 10.1111/vox.13244

Year: 2022

Longitudinal Trends in Bleeding Complications on Extracorporeal Life Support Over the Past Two Decades-Extracorporeal Life Support Organization Registry Analysis.

DOI: 10.1097/ccm.0000000000005466

Year: 2022

Economic Evaluation of National Patient Blood Management Clinical Guidelines in Cardiac Surgery.

DOI: 10.1016/j.jval.2021.07.014

Year: 2022

Determinants of passive antibody effectiveness in SARS-CoV-2 infection

DOI: 10.1101/2022.03.21.22272672

Year: 2022

Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia

DOI: 10.1080/10428194.2021.2012664

Year: 2021

Blood Spotlight How should we use convalescent plasma therapies for the management of COVID-19?

DOI:

Year: 2021

Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR)

DOI: 10.1038/s41409-021-01308-8

Year: 2021

How are Resistant Infections Monitored?

What Are the Limitations of Random Networks?

How Can Pharmacy Refill Records Be Integrated with Other Data Sources?

What are Epidemiological Pathways?

Why are Regions Important in Epidemiology?

How Can Health Educators Improve Public Health Outcomes?

Are There Any Economic Impacts?

How Do Adaptive Clinical Trials Work?

What are Cysticerci?

What are some examples of secondary prevention?

Partnered Content Networks

Relevant Topics